Taysha Gene Therapies (TSHA) Return on Equity (2020 - 2026)

Taysha Gene Therapies has disclosed Return on Equity across 7 years of filings, most recently posting 0.01% for Q1 2026.

• Return on Equity for Q1 2026 came in at 0.01%, up 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (up 1.0% YoY), and the FY2025 annual result was 0.01%, up 1.0% from the prior year.
• Return on Equity came in at 0.01% for Q1 2026 at Taysha Gene Therapies, down from 0.0% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.19% in Q1 2023 to a low of 0.28% in Q4 2022.
• The 5-year median for Return on Equity is 0.01% (2024), against an average of 0.02%.
• Across the five-year window, Return on Equity slipped 27 bps in 2022 and grew 23 bps in 2023, its largest moves.
• Taysha Gene Therapies' Return on Equity stood at 0.28% in 2022, then surged by 80 bps to 0.06% in 2023, then soared by 82 bps to 0.01% in 2024, then surged by 59 bps to 0.0% in 2025, then dropped by 22 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.